Objective: The treatment of multiple sclerosis (MS) with disease-modifying-drugs (DMDs) is evolving and new drugs are reaching the market. Efficacy and safety aspects of the drugs are crucial, but the patients' satisfaction with the treatment must be taken into consideration.
Methods: Individual interview with patients with MS regarding their satisfaction and points of view on the treatment with DMDs.
Results: One hundred and twenty eight patients attending specialized MS Units in five different cities were interviewed. Over 80% of patients were very satisfied with the drugs in use regarding convenience and perceived benefits. The only aspect scoring lesser values was tolerability.
Conclusion: Parameters for improving treatment in MS must include efficacy, safety, and patient satisfaction with the given DMD.